

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Analgesics, in acute herpes zoster, 544
- Antibiotic pharmacokinetics, age-related changes in, and impact on dosing, 444, 445
 - aging and, 444–446
 - and changes in body composition, 445, 446
- Antibiotic therapy, in bacterial pneumonia, 468–471
 - initial, choosing of, 447
 - optimal, prescription of, 448–450
- Antibiotic use, in older adults, 443, 444
 - impact of, 444
- Antibiotics, administration of, choosing route of, 450–451
 - and absorption by gastrointestinal tract, 450–451
 - and interactions with common drugs, 453–454
 - β -lactam, choosing of, antimicrobial susceptibilities and, 448–450
 - bactericidal, 450
 - immuologic reactions to, 453
 - in *Clostridium difficile* infection, 517, 518
 - patient response to, and side effects of, 451
 - use in hospital and long-term care facilities, 454–455
- Antimicrobial agents, eliminated by hepatic metabolism, 446
 - side effects of, by organ system, 452–453
- Antimicrobial therapy, in urinary tract infections, 529–531
 - principles of, in older adults, **443–457**
- Antiretroviral therapy, timing of, in human immunodeficiency virus, 575
- Antiviral therapy, in acute herpes zoster, 542–544
- Appendix, infections of, 500

B

- B-cell aging, 423–424
- Bacteriuria, asymptomatic, treatment of, 529
- Biliary tract, infections of, 497–498
- Biofilm, bone and joint infections and, 557
- Bone and joint infections, biofilm and, 557
 - differential diagnosis of, 558
 - frailty and, 556
 - host factors for, in elderly patients, 556–557
 - in older adults, **555–570**
- Bowel, small, infections of, 500
- Buried bumper syndrome, chronic, 499

C

- Capsaicin, in postherpetic neuralgia, 548
- Catheter, indwelling, urinary tract infections in, 532–533
- Cephalosporins, 450
- Clostridium difficile*, causing wide spectrum of infection, 514
- Clostridium difficile* infection, clinical manifestations of, 516
 - epidemiology of, 514–515
 - intraabdominal, 502
 - laboratory diagnosis of, 516–517
 - pathogenesis of, 515
 - prevention of, 519
 - risk factors for, 515–516
 - treatment of, 517–519
- Colon, infections of, 501–502
- Corticosteroids, in acute herpes zoster, 544
- Creatinine clearance, in older adults, 446

D

- Dendritic cells, age-related changes in, 418
- Diabetes mellitus, human immunodeficiency virus and, 578
- Diabetic foot infections, 560–561
- Diarrhea, infectious, **509–522**
 - Clostridium difficile* as cause of. See *Clostridium difficile* infection.
 - norovirus as cause of. See *Norovirus*.
- Diphtheria toxoid, reduced, 622
- Diphtheria vaccination, 619
- Duodenum, and stomach, infections of, 498–500

F

- Fecal microbiota transplant, in *Clostridium difficile* infection, 517–519
- Fever, as adaptive host defense mechanism, 436–437
 - criterion for, 438
 - pathogenesis of, 437
 - significance of, temperature, and fever of unknown origin, 438–439
- Foot, diabetic infections of, 560–561
- Frailty, and bone and joint infections, 556

G

- Gabapentin, in postherpetic neuralgia, 545–548
- Gastrostomy tube(s), acute migration of, 499
 - complications of, 499
 - displacement of internal balloon of, 499–500
- Glucocorticoids, in bacterial pneumonia, 471

H

- Herpes zoster, **539–553**
 - clinical features of, 540–542

- diagnosis of, 542
 - epidemiology of, 540
 - in aging, 539–540
 - prevention of, 549–551
 - rash due to, 541
 - treatment of, 542–545
- Hip replacement, and knee replacement, prosthetic joint infections in, 561
- Host resistance, and immune aging, **415–432**
- Human immunodeficiency virus, complications of, 576
- diagnosis of, and case definition, 572, 574
 - epidemiology of, 572, 573
 - incident diabetes mellitus and, 578
 - kidney disease in, 579
 - liver disease in, 579
 - metabolic syndrome and, 579
 - neurocognitive deficits in, 579
 - osteoporosis in, 579
 - prevention of, 580
 - pulmonary disease in, 580
 - treatment of, 574–576
 - response to, 575
 - selection of, 575, 576, 577–578
 - timing of antiretroviral therapy in, 575
- Human immunodeficiency virus/acquired immunodeficiency syndrome, in older adults, **571–583**

I

- Immune aging, host resistance and, **415–432**
- systems analysis of, 424–425
- Immune response, altered, studies in, future directions in, 425
- Immune system, adaptive, age-associated alterations in, 424
- changes with aging, 420–424
 - innate, age-related alterations in, 419–420, 421
 - inflammatory dysregulation in, 416
- Immunity, innate, changes in, 416–420
- Immunologic function, changes in, 415–416
- Immunotherapy, in *Clostridium difficile* infection, 517
- Infection(s), blunted febrile response to, 435–437
- clinical features of, in older adults, **433–441**
 - diabetic, of foot, 560–561
 - in nursing homes. See *Nursing homes, infections in.*
 - intraabdominal, anatomic classification of, 493–494
 - clinical evaluation of, 494–495
 - Clostridium difficile* infection, 501–502
 - important considerations in, 496–497
 - in older adults, **493–507**
 - management options in, 495–496
 - of appendix, 500
 - of biliary tract, 497–498
 - of colon, 500–501

Infection(s) (*continued*)

- of pancreas, spleen, and liver, 502–503
 - of small bowel, 498–500
 - of stomach and duodenum, 498–500
 - nonclassical presentations of, 435, 436
 - of prosthetic joints. *See Prosthetic joint infections.*
 - presumptive, initial approach to, 447, 448
- Infectious diseases, presentation of, in old age, 434–435
- Inflammation, age-related, origins of, 419–420
- dysregulation of, age-related, 416
- Influenza, and influenza vaccination, 610–613
- epidemiology of, 610–611
- Influenza vaccination, effectiveness of, 611, 612
- influenza and, 610–613
 - of health care workers, 613–614
- Influenza vaccines, and vaccine administration, 613
- effects on cardiovascular events, 611, 612
 - for use in adults 65 years old and older, 611, 613

J

- Joints, infections of, osteoarthritis and, 556, 557
- native, infections of, 557–559
 - prosthetic, infections of. *See Prosthetic joint infections.*

K

- Knee replacement, and hip replacement, prosthetic joint infections in, 561

L

- Lidocaine patch, topical, in postherpetic neuralgia, 545
- Liver, infections of, 502–503

M

- Monocytes, innate immune responses and, 417–418

N

- Natural killer cells, age-related changes in, 418–419
- Neutrophils, function with age, 416–417
- Norovirus, 509–514
- burden in United States, 509, 510
 - clinical manifestations of, 512
 - diagnosis of, 512
 - prevention/intervention in, 513
 - symptoms of, 511
 - transmission electron micrograph of, 509, 510
 - transmission of, 511–512
 - treatment of, 512–513

- Norovirus vaccines and antivirals, 513–514
- Nortriptyline, in postherpetic neuralgia, 548
- Nursing homes, antibiotic use in, 586
 - infections in, antibiotic stewardship programs in, 592
 - burden of, and importance of colonization, 588–590
 - common, epidemiology of, 588–591
 - diagnosis of, challenges of, 592
 - due to exposure to infectious materials, 595
 - environmental-level and institutional-level, risk factors for, 586
 - inappropriate use of antibiotics in, 588, 589
 - lower respiratory tract, 591
 - prevention and control programs in, 592–601
 - device care and, 598–599
 - hand hygiene and, 597–598
 - infection control committee and, 593
 - isolation precautions in, 595
 - key elements in, 593–597
 - multidrug-resistant organism prevention and, 599, 600
 - staff education and, 599–601
 - transmission-based precautions in, 595, 596
 - recognition of, and antimicrobial programs in, 591–592
 - resident risk factors for, 586
 - risk factors for, 586–588
 - skin and soft tissue, 591
 - urinary tract, 590–591

O

- Opioids, in postherpetic neuralgia, 548
- Osteoarthritis, joint infections and, 556, 557
- Osteomyelitis, bone and joint infections and, 555–556, 560–561
 - chronic, 559–560
 - classification of, 560
 - incidence of, 560
 - treatment of, 560–561

P

- Pancreas, infections of, 502
- Pertussis acellular vaccination, 622
- Pertussis (whooping cough), incidence of, 619, 622
- Pneumococcal disease, and pneumococcal vaccination, 614–615
 - epidemiology of, 614–615
- Pneumococcal vaccination, pneumococcal disease and, 614–615
- Pneumococcal vaccine(s), administration recommendations, 616–618
 - conjugated, 616, 617
 - polysaccharide, 614–615
- Pneumonia, acute care hospital management in, 434
 - bacterial, antibiotic therapy in, 468–471
 - care in, decision of site for, 466–468
 - causes of, 460

Pneumonia (*continued*)

- and etiologic diagnosis of, 462
- clinical features of, 464–465
- community-acquired, cause in European countries, 462–463
- comorbid illnesses in, 462, 463
- components of care in, 470, 471–472
- epidemiology of, 460–462
- failure to improve with therapy, considerations in, 470–471
- glucocorticoids in, 471
- in older adults, **459–477**
- increased weight and lung consolidation in, 460
- long-term outcomes of, 472
- pathogenesis of, 461–462
- radiographic assessment of, 465–466
- risk factors for, 461–462
- patient presentation in, 435
- Postherpetic neuralgia, noninvasive treatments in, 549
 - pharmacotherapy in, 545–549
 - treatment of, 545–549
- Probiotics, in *Clostridium difficile* infection, 517
- Prosthetic joint infections, 555, 561–566
 - after knee and hip replacement, 561
 - diagnosis of, 562
 - joint aspiration in, 562–563
 - radiographs in, 562, 563
 - risk factors for, 562
 - spacers in, 564, 565
 - treatment of, 563–566

S

- Spleen, infections of, 502–503
- Stomach, and duodenum, infections of, 498–500

T

- T-cell aging, 420–423
- Temperature, baseline, significance of fever, and fever of unknown origin, 438–439
- Tetanus, clinical manifestations of, 618
- Tetanus toxoid, 622
- Tuberculosis, chest radiography and computer-aided diagnosis in, 483–484
 - clinical characteristics of, 482
 - diagnosis of, 482–485
 - epidemiology of, 480–481
 - in older adults, **479–491**
 - infection control issues in, 489
 - interferon-gamma release assays in, 483
 - laboratory diagnosis in, 484
 - latent, treatment of, 488–489
 - lipoarabinomannan as biomarker in, 485
 - molecular diagnostics in, 484–485

- pathogenesis of, 481–482
- serologic tests in, 485
- treatment of, 485–488
- tuberculin skin testing in, 482–483
 - reactions to, 488–489

U

- Urinary tract infections, antimicrobial treatment of, 529–531
 - duration of, 531
 - prophylactic, 531
- association with estrogen therapy, in postmenopausal women, 526
- diagnosis of, in community population, 527–528
 - in long-term care facility, 528
- epidemiology of, 524–525
- in community populations, 524–525
- in indwelling catheter, diagnosis of, 532–533
 - epidemiology of, 532
 - pathogenesis of, 532
 - prevention of, 533
 - treatment of, 533
- in institutionalized populations, 525
- in nursing homes, 590–591
- in older adult, **523–538**
- laboratory diagnosis of, 528–529
 - urine culture in, 528–529
- microbiology of, in community population, 527
- pathogenesis of, in community population, 525
 - in long-term care facility, 527
- prevention of, 531
- symptomatic, asymptomatic bacteriuria and, 524

V

- Vaccinations, for individuals with chronic disease and immunocompromised states, 618
 - for older adult, **609–625**
 - recommendations for adults 65 years and older, 618–619, 623
 - to prevent disease, incidence and cost of, 609, 610

Z

- Zoster vaccine, live attenuated, 549–551
 - subunit adjuvanted, 551